Claire Verschraegen

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi request reprint TLK-286
    Claire F Verschraegen
    University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA
    IDrugs 7:771-81. 2004
  2. doi request reprint Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 64:287-95. 2009
  3. ncbi request reprint KW-2170 (Kyowa Hakko Kogyo)
    Claire F Verschraegen
    UNM Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque, NM 87131, USA
    IDrugs 5:1000-3. 2002
  4. pmc Ratios of involved nodes in early breast cancer
    Vincent Vinh-Hung
    Oncology Center, Academic Hospital, AZ VUB, Vrije Universiteit Brussel, Jette, Belgium
    Breast Cancer Res 6:R680-8. 2004
  5. doi request reprint Novel chemotherapy approaches for cervical cancer
    Sujana Movva
    Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico, USA
    Cancer 115:3166-80. 2009
  6. ncbi request reprint Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies
    Claire F Verschraegen
    Cancer Research and Treatment Center, University of New Mexico, Albequerque, New Mexico 87131, USA
    Clin Cancer Res 10:2319-26. 2004
  7. pmc Modeling the effect of tumor size in early breast cancer
    Claire Verschraegen
    Division of Hematology Oncology, Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico 87131, USA
    Ann Surg 241:309-18. 2005
  8. ncbi request reprint A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
    Claire F Verschraegen
    Section of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Chemother Pharmacol 53:1-7. 2004
  9. ncbi request reprint Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles
    C F Verschraegen
    University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, NM 87131, Albuquerque, New Mexico, USA
    J Cancer Res Clin Oncol 129:549-55. 2003
  10. ncbi request reprint Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer
    Claire F Verschraegen
    Multidisciplinary Gynecologic Oncology Center, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 90:552-9. 2003

Detail Information

Publications43

  1. ncbi request reprint TLK-286
    Claire F Verschraegen
    University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA
    IDrugs 7:771-81. 2004
    ..Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer...
  2. doi request reprint Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 64:287-95. 2009
    ..This study was designed to determine the MTD and pharmacology of PPX administered weekly to patients with solid malignancies...
  3. ncbi request reprint KW-2170 (Kyowa Hakko Kogyo)
    Claire F Verschraegen
    UNM Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque, NM 87131, USA
    IDrugs 5:1000-3. 2002
    ..By August 2002, Japanese phase I trials had been completed [460177]...
  4. pmc Ratios of involved nodes in early breast cancer
    Vincent Vinh-Hung
    Oncology Center, Academic Hospital, AZ VUB, Vrije Universiteit Brussel, Jette, Belgium
    Breast Cancer Res 6:R680-8. 2004
    ....
  5. doi request reprint Novel chemotherapy approaches for cervical cancer
    Sujana Movva
    Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico, USA
    Cancer 115:3166-80. 2009
    ..The use of novel therapeutic approaches targeted to the carcinogenic processes that leads to the ontogenesis of cervical cancer should be promoted in clinical studies to improve patient outcomes...
  6. ncbi request reprint Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies
    Claire F Verschraegen
    Cancer Research and Treatment Center, University of New Mexico, Albequerque, New Mexico 87131, USA
    Clin Cancer Res 10:2319-26. 2004
    ....
  7. pmc Modeling the effect of tumor size in early breast cancer
    Claire Verschraegen
    Division of Hematology Oncology, Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico 87131, USA
    Ann Surg 241:309-18. 2005
    ..The purpose of this study was to determine the type of relationship between tumor size and mortality in early breast carcinoma...
  8. ncbi request reprint A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
    Claire F Verschraegen
    Section of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Chemother Pharmacol 53:1-7. 2004
    ....
  9. ncbi request reprint Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles
    C F Verschraegen
    University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, NM 87131, Albuquerque, New Mexico, USA
    J Cancer Res Clin Oncol 129:549-55. 2003
    ..To perform a phase I study of intraperitoneal cis-bis-neodecanoato ( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles (L-NDDP) for peritoneal carcinomatosis or sarcomatosis...
  10. ncbi request reprint Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer
    Claire F Verschraegen
    Multidisciplinary Gynecologic Oncology Center, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 90:552-9. 2003
    ..About 80% of primary ovarian cancers and cell lines bear LHRH receptors. Cetrorelix has anticancer activity in in vitro and in vivo ovarian cancer models...
  11. doi request reprint A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
    Claire F Verschraegen
    University of New Mexico Cancer Research and Treatment Center, 900 Camino de Salud, Albuquerque, NM 87131, USA
    Cancer Chemother Pharmacol 63:903-10. 2009
    ..Determine the toxicity, maximum tolerated dose (MTD), and pharmacokinetics of paclitaxel poliglumex (PPX; CT-2103) in combination with cisplatin administered every 3 weeks...
  12. ncbi request reprint Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers
    Claire F Verschraegen
    Department of Gynecologic Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:845-52. 2003
    ..The purpose of this study was to characterize cell cultures and xenografts derived from patients with ovarian cancer...
  13. ncbi request reprint Irinotecan for the treatment of cervical cancer
    Claire F Verschraegen
    Cancer Research and Treatment Center, University of New Mexico, Albuquerque 87131, USA
    Oncology (Williston Park) 16:32-4. 2002
    ..Gastrointestinal toxicities have been particularly problematic at high irinotecan doses. Further studies of irinotecan in combination with other drugs and radiotherapy are warranted...
  14. ncbi request reprint Malignant adnexal masses in pregnancy
    Hamid Sayar
    Cancer Research and Treatment Center, Division of Hematology Oncology, University of New Mexico, 900 Camino de Salud NE, Albuquerque, NM 87131, USA
    Obstet Gynecol Clin North Am 32:569-93. 2005
    ..It is imperative to care for the patient with a multidisciplinary team that includes a high-risk obstetrician, a gynecologic oncologist, and a medical oncologist specialized in gynecologic cancers...
  15. ncbi request reprint Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas
    Ralph S Freedman
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5228-37. 2003
    ..p. and s.c. administration of fms-like tyrosine kinase-3-ligand (Flt3-L; Amgen, Thousand Oaks, CA), a truncated glycoprotein that increases dendritic cells (DCs) and monocytes...
  16. pmc GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM, USA
    Breast Cancer Res Treat 123:51-8. 2010
    ..These findings suggest potential new therapeutic targets for IBC such as novel endocrine agents or direct modulation of GPR30...
  17. ncbi request reprint Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma
    Renato Lenzi
    Department of Gastrointestinal Medical, Memorial Hermann Hospital, Houston, Texas, USA
    Clin Cancer Res 8:3686-95. 2002
    ..The purpose is to determine dose-limiting toxicity, pharmacokinetics,pharmacodynamics, and immunobiology after i.p. injections of recombinant human IL-12 (rhIL-12)...
  18. ncbi request reprint A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer
    Judith K Wolf
    Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77030, USA
    Gynecol Oncol 102:468-74. 2006
    ..To determine the efficacy, toxicity, and quality of life of capecitabine (Xeloda), an oral 5-fluorouracil derivative, in patients with chemorefractory recurrent mullerian cancers...
  19. pmc Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells
    Elizabeth A Williamson
    Department of Internal Medicine, University of New Mexico Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87131, USA
    Invest New Drugs 30:114-20. 2012
    ....
  20. doi request reprint A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies
    Julie Bauman
    Division of Hematology Oncology, University of New Mexico Cancer Center, Albuquerque, NM, USA
    Cancer Chemother Pharmacol 69:547-54. 2012
    ..Epigenetic therapy to reactivate tumor suppressor genes may enhance the anti-proliferative effect of erlotinib. This phase I study evaluated the combination of erlotinib and 5-azacytidine for safety and maximal tolerated dose (MTD)...
  21. ncbi request reprint The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
    Sujana Movva
    University of New Mexico Cancer Research and Treatment Center, Division of Hematology Oncology, Albuquerque, NM 87131, USA
    Expert Opin Biol Ther 9:231-41. 2009
    ..Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T cell immune response against tumor cells. Ipilimumab (MDX-010) is a monoclonal antibody directed against CTLA-4...
  22. doi request reprint Irinotecan use during pregnancy
    Justin Taylor
    Division of Hematology Oncology, University of New Mexico Cancer Center, Department of Gynecology and Obstetrics, University of New Mexico, Albuquerque, New Mexico 87131, USA
    Obstet Gynecol 114:451-2. 2009
    ..Ovarian tumors during pregnancy are rare. There is sparse clinical evidence about the safety of chemotherapy in this situation...
  23. ncbi request reprint A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer
    Donghai Dai
    Reproductive Molecular Biology Laboratory, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology
    Cancer Res 65:9517-24. 2005
    ..The dual specificity of amifostine action should be further investigated...
  24. doi request reprint A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer
    Houman M Fekrazad
    University of New Mexico Cancer Center, Albuquerque, USA
    Am J Clin Oncol 33:393-7. 2010
    ..Flavopiridol synergizes in a sequence-dependent fashion with chemotherapy. Major adverse events of flavopiridol in single agent phase I studies are secretory diarrhea, neutropenia, thrombosis, and fatigue...
  25. ncbi request reprint Changing trends in gestational trophoblastic disease
    Harriet O Smith
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 5286, USA
    J Reprod Med 51:777-84. 2006
    ..The New Mexico Tumor Registry (NMTR) and Surveillance, Epidemiology and End Results (SEER) registries were utilized to determine (30+)-year trends in gestational trophoblastic disease and choriocarcinoma...
  26. pmc Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM 87131 5636, USA
    Gynecol Oncol 114:480-5. 2009
    ..This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors...
  27. ncbi request reprint Gestational trophoblastic neoplasia in American Indians
    Harriet O Smith
    New Mexico Tumor Registry, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque 87131 5286, USA
    J Reprod Med 49:535-44. 2004
    ..To analyze gestational trophoblastic neoplasia (GTN) trends among American Indians (AI) using population-based data...
  28. ncbi request reprint Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma
    Duc Thanh Le
    Departments of Gynecologic Medical Oncology, General Surgery, and Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Invest 21:682-9. 2003
    ..There were no grade > or = 3 hematologic toxicities. The combination of cisplatin and CPT-11 is well tolerated and has clinical benefits in patients with peritoneal mesothelioma...
  29. ncbi request reprint Incidence and survival rates for female malignant germ cell tumors
    Harriet O Smith
    Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5286, USA
    Obstet Gynecol 107:1075-85. 2006
    ..To evaluate 30-year, population-based trends in incidence and survival rates for malignant germ cell tumors originating within the female genital tract...
  30. ncbi request reprint Alternative administration of camptothecin analogues
    Ursa Glaberman
    University of New Mexico Cancer Research and Treatment Center, Albuquerque, 87131, USA
    Expert Opin Drug Deliv 2:323-33. 2005
    ..Transdermal administration of rubitecan has been studied in mice. So far, no CPT has been approved for an alternative route of administration...
  31. doi request reprint Locally advanced cervical cancer: what is the standard of care?
    Zeina Al-Mansour
    The University of New Mexico Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87131, USA
    Curr Opin Oncol 22:503-12. 2010
    ..Locally advanced cervical cancer (LACC) is a common presentation that has been extensively studied in the last three decades. This article reviews the standard of care and discusses current topics of clinical research...
  32. ncbi request reprint Cyclin E deregulation alters the biologic properties of ovarian cancer cells
    Isabelle Bedrosian
    Department of Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Oncogene 23:2648-57. 2004
    ..Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors...
  33. ncbi request reprint Tasidotin HCl (Genzyme)
    Kanwaldeep Kaur Rasila
    The University of New Mexico Cancer Research and Treatment Center, Division of Hematology Oncology, 900 Camino de Salud NE, Albuquerque, NM 87131, USA
    Curr Opin Investig Drugs 6:631-8. 2005
  34. doi request reprint Rate of thromboembolic events in mesothelioma
    Derrick Nguyen
    University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, USA
    Ann Thorac Surg 85:1032-8. 2008
    ..This retrospective study attempts to determine the rates of TEE in patients with mesothelioma...
  35. ncbi request reprint Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer
    Wei Hu
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Res 15:49-57. 2005
    ..Overexpression of STK15 with coordinate loss of wild-type p53 function thus appears to play an important role in ovarian tumorigenesis and offers a novel molecular target in designing effective therapy of human ovarian cancer...
  36. ncbi request reprint SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers
    David A Mills
    The University of New Mexico Cancer Center, 900 Camino de Salud, NE, Albuquerque, NM 87131, USA
    Curr Opin Investig Drugs 9:647-57. 2008
    ..A phase II clinical trial in patients with platinum-resistant ovarian cancer and phase I/II and phase II clinical trials in patients with acute leukemias were ongoing at the time of publication...
  37. ncbi request reprint Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor
    Wei Hu
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Proteomics 3:1904-11. 2003
    ....
  38. doi request reprint Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols
    Alonso V Pacheco
    The University of New Mexico, Cancer Research and Treatment Center, Albuquerque, NM 87131, USA
    Urol Oncol 26:610-5. 2008
    ....
  39. ncbi request reprint Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor
    Wei Hu
    Department of Gynecologic and Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Anticancer Res 22:665-72. 2002
    ..HSPs may therefore be an important molecular target for drug intervention strategies...
  40. ncbi request reprint Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas
    Qian Li
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Anticancer Res 24:1327-35. 2004
    ....
  41. doi request reprint Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, MRC 4W, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    J Clin Oncol 26:3567-72. 2008
    ..This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM...
  42. ncbi request reprint Diagnosis, staging, and surveillance of cervical carcinoma
    Harmeet Kaur
    Division of Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 57, Houston 77030, USA
    AJR Am J Roentgenol 180:1621-31. 2003
  43. ncbi request reprint Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study
    Saroj Vadhan-Raj
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 359:2145-52. 2002
    ..We aimed to compare the safety and efficacy of this strategy with that of transfusion with fresh allogeneic platelets in patients with severe chemotherapy-induced thrombocytopenia...